A study in Israel, comparing use of ustekinumab (Stelara) and 3 other biologics used to treat inflammatory conditions has found that patients stayed on the drug longer compared with its comparators.
The authors of the study conducted a “drug survival” analysis among 907 patients with severe psoriasis who received adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), and ustekinumab for the treatment of psoriasis, using data drawn from a large health maintenance organization in Israel.
In their patient cohort, the authors documented 1575 biologic treatments and 865 discontinuation of treatments. Ustekinumab, which inhibits interleukin 12 and 23, had a significantly higher survival rate (40.8 months) than either one of the other 3 drugs, all tumor necrosis factor inhibitors. Adalimumab averaged at 26.4 months, etanercept at 26.35 months, and infliximab at 23.9 months.
Important positive predictors of drug survival, the authors report, included treatment naivety and concomitant methotrexate intake. On the other hand, duration of the previous treatment as well as female gender were negative predictors of survival.
The authors concluded that biologics efficacy in real-life clinical practice decreases over time. They also noted that while ustekinumab survived longer among patients, most of its use was as a third-line in patients with severe psoriasis.
Reference
Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients [published online December 28, 2016]. J Am Acad Dermatol. pii: S0190-9622(16)31008-8. doi: 10.1016/j.jaad.2016.10.033.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
March 19th 2025Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Retina Specialists’ Evolving View on Biosimilars in AMD Treatment
March 16th 2025The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies for their patients, according to Paul Hahn, MD, PhD, FASRS, a retina specialist at NJ Retina.